<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Q32 Bio Inc — News on 6ix</title>
<link>https://6ix.com/company/q32-bio-inc</link>
<description>Latest news and press releases for Q32 Bio Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/q32-bio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b4cc78dffbe2df113504.webp</url>
<title>Q32 Bio Inc</title>
<link>https://6ix.com/company/q32-bio-inc</link>
</image>
<item>
<title>Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative</description>
</item>
<item>
<title>Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-reports-fourth-quarter-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-reports-fourth-quarter-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data</description>
</item>
<item>
<title>Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Wed, 18 Feb 2026 11:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.</description>
</item>
<item>
<title>Q32 Bio Announces $10.5 Million Registered Direct Offering</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-announces-dollar105-million-registered-direct-offering</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-announces-dollar105-million-registered-direct-offering</guid>
<pubDate>Tue, 17 Feb 2026 11:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced a $10.5 million registered direct offering. This transaction was led by a new institutional investor with participation by an existing dedicated public institutional investor.</description>
</item>
<item>
<title>Q32 Bio Sells Complement Inhibitor ADX-097</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-sells-complement-inhibitor-120000762</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-sells-complement-inhibitor-120000762</guid>
<pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
<description>Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (NASDAQ: AKBA) ("Akebia").</description>
</item>
<item>
<title>Akebia Announces Establishment of Rare Kidney Disease Pipeline</title>
<link>https://6ix.com/company/q32-bio-inc/news/akebia-announces-establishment-of-rare-kidney-disease-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/akebia-announces-establishment-of-rare-kidney-disease-pipeline</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement</description>
</item>
<item>
<title>Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-reports-third-quarter-115900199</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-reports-third-quarter-115900199</guid>
<pubDate>Thu, 13 Nov 2025 11:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended September 30, 2025, and provided recent corporate updates.</description>
</item>
<item>
<title>Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-announces-completion-enrollment-105900542</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-announces-completion-enrollment-105900542</guid>
<pubDate>Tue, 21 Oct 2025 10:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.</description>
</item>
<item>
<title>Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-participate-2025-wells-105900470</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-participate-2025-wells-105900470</guid>
<pubDate>Thu, 28 Aug 2025 10:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 3:45 p.m. E.T. on Thursday, September 4th at the 2025 Wells Fargo Healthcare Conference.</description>
</item>
<item>
<title>Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-reports-second-quarter-105900215</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-reports-second-quarter-105900215</guid>
<pubDate>Wed, 06 Aug 2025 10:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended June 30, 2025, and provided recent corporate updates.</description>
</item>
<item>
<title>Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-appoints-adrien-sipos-105900009</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-appoints-adrien-sipos-105900009</guid>
<pubDate>Wed, 25 Jun 2025 10:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the appointment of Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer. Dr. Sipos succeeds Jason Campagna, M.D., Ph.D., who will be departing the company.</description>
</item>
<item>
<title>OXB completes acquisition of remaining stake in US subsidiary</title>
<link>https://6ix.com/company/q32-bio-inc/news/oxb-completes-acquisition-of-remaining-stake-in-us-subsidiary</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/oxb-completes-acquisition-of-remaining-stake-in-us-subsidiary</guid>
<pubDate>Mon, 23 Jun 2025 11:00:00 GMT</pubDate>
<description>OXB completes acquisition of remaining stake in US subsidiary Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has acquired the remaining 10% stake in its US subsidiary from Q32 Bio, Inc. (Q32), bringing its ownership, as planned, to 100%. As previously disclosed in the Co</description>
</item>
<item>
<title>Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-reports-first-quarter-105900440</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-reports-first-quarter-105900440</guid>
<pubDate>Thu, 08 May 2025 10:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates.</description>
</item>
<item>
<title>Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-announces-fda-fast-105900537</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-announces-fda-fast-105900537</guid>
<pubDate>Wed, 30 Apr 2025 10:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designation (FTD) to Q32 Bio's bempikibart (ADX-914) for the treatment of AA. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signalin</description>
</item>
<item>
<title>Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-doses-first-patients-105900578</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-doses-first-patients-105900578</guid>
<pubDate>Wed, 16 Apr 2025 10:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata (AA).</description>
</item>
<item>
<title>Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-reports-fourth-quarter-105900579</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-reports-fourth-quarter-105900579</guid>
<pubDate>Tue, 11 Mar 2025 10:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended December 31, 2024, and provided recent corporate updates.</description>
</item>
<item>
<title>Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-presents-results-signal-160000777</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-presents-results-signal-160000777</guid>
<pubDate>Sat, 08 Mar 2025 16:00:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy of Dermatology (AAD) Meeting in Orlando, FL. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling t</description>
</item>
<item>
<title>Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-announces-breaking-presentation-140000526</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-announces-breaking-presentation-140000526</guid>
<pubDate>Fri, 28 Feb 2025 14:00:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) will be presented in a late-breaking oral session at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place March 7-11 in Orlando, FL. Bempikibart is a fully human anti-IL-7Rα antibody that</description>
</item>
<item>
<title>Q32 Bio to Participate in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-participate-upcoming-march-115900589</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-participate-upcoming-march-115900589</guid>
<pubDate>Wed, 26 Feb 2025 11:59:00 GMT</pubDate>
<description>Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in March:</description>
</item>
<item>
<title>Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata</title>
<link>https://6ix.com/company/q32-bio-inc/news/q32-bio-announces-strategic-restructuring-to-focus-on-advancement-of-bempikibart-in-patients-with-alopecia-areata</link>
<guid isPermaLink="true">https://6ix.com/company/q32-bio-inc/news/q32-bio-announces-strategic-restructuring-to-focus-on-advancement-of-bempikibart-in-patients-with-alopecia-areata</guid>
<pubDate>Mon, 10 Feb 2025 05:00:00 GMT</pubDate>
<description>-- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company</description>
</item>
</channel>
</rss>